Skip to content

Avinash Hosanagar

4 papers in the library · 28 citations · publishing 2021-2025

Papers

Sort Most recent Most cited

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial

Frontiers in Pain Research March 18, 2025 Jenna McAfee, Avinash Hosanagar, Vijay Tarnal et al. 18 citations

Introduction Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Currently, there are limited treatment options available that effectively treat FM symptoms. Psilocybin-assisted therapy (PAT) is an emerging combined drug-therapy intervention, but no studies to-date have investigated PAT for FM. Methods...

DOI: 10.3389/fpain.2025.1527783 (opens in new tab) Psilocybin Clinical trial Fibromyalgia Open label +2

Trainees Unprepared for Advances in Psychedelic Medicine: A Survey Study.

Journal of Psychoactive Drugs 2025 Jamarie Geller, Nicolas G. Glynos, Andrew Lemmen et al.

This study aimed to characterize attitudes and identify gaps in trainee knowledge and education that may impact the field's readiness for the reemergence of psychedelic use in psychiatry. A two-part survey was sent out targeting medical and allied professional trainees who may interact with patients using or planning to use psychedelics therapeutically. Collected data for part one characterized...

DOI: 10.1080/02791072.2024.2341795 (opens in new tab) Full text (opens in new tab) Psychedelics Education Psychedelic medicine Training

Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1

The Journal of Clinical Psychiatry February 23, 2021 Avinash Hosanagar, Joseph Michael Cusimano, Rajiv Radhakrishnan 9 citations

PsilocybinPsilocybin, derived from mushrooms belonging to the genus Psilocybe, and psilocin, its active metabolite, are indolamines.Recent studies have shown that psilocybin has effects on brain functional connectivity.14 Its effects include reducing negative affect and amygdala response to emotional faces at 1 week, with enduring changes in resting state functional connectivity (RSFC) at 1...

Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2

The Journal of Clinical Psychiatry February 23, 2021 Avinash Hosanagar, Joseph Cusimano, Rajiv Radhakrishnan 1 citation

P sychedelics have recently gained attention as compounds with therapeutic potential in the treatment of psychiatric disorders.The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designations for (±)-3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy in severe posttraumatic stress disorder (PTSD) (in 2017) and for the adjunctive use of psilocybin with...